Skip to Content

Mifepristone Pregnancy and Breastfeeding Warnings

Mifepristone is also known as: Korlym, Mifeprex

Mifepristone Pregnancy Warnings

Mifepristone for abortion: Because mifepristone is indicated for use during early pregnancy, it has not been formally assigned to a pregnancy category by the FDA. Fetal deformities have been reported in animal studies but were most likely the result of mechanical effects of uterine contractions caused by decreased progesterone levels. Controlled data in human pregnancy have illustrated mifepristone's labeled efficacy. The manufacturer recommends mifepristone only be administered for termination of early pregnancy (through 49 days) after the treatment procedure, and its effects, have been discussed with the patient. Mifepristone for hyperglycemia: Mifepristone has been assigned to pregnancy category X by the FDA. Mifepristone can cause fetal harm when administered to a pregnant woman because the use of mifepristone results in pregnancy loss. The inhibition of both endogenous and exogenous progesterone by mifepristone at the progesterone receptor results in pregnancy loss. If mifepristone is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. Mifepristone use is considered contraindicated in pregnancy.

See references

Mifepristone Breastfeeding Warnings

There are no data on the excretion of mifepristone into human milk. Because many drugs are excreted into human milk and because of the risk of adverse effects in the nursing infant, a decision should be made whether to discontinue the drug or discontinue nursing, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Mifeprex (mifepristone)" Danco Laboratories, New York, NY.
  2. "Product Information. Korlym (mifepristone)." Corcept Therapeutics Incorporated, Menlo Park, CA.

References for breastfeeding information

  1. "Product Information. Korlym (mifepristone)." Corcept Therapeutics Incorporated, Menlo Park, CA.
  2. "Product Information. Mifeprex (mifepristone)" Danco Laboratories, New York, NY.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.